Retrospective Study
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 7, 2014; 20(41): 15358-15366
Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15358
Hepatitis B vaccination in patients with inflammatory bowel disease
Ruwaida Ben Musa, Anuhya Gampa, Sanjib Basu, Ali Keshavarzian, Garth Swanson, Michael Brown, Rana Abraham, Keith Bruninga, John Losurdo, Mark DeMeo, Sohrab Mobarhan, David Shapiro, Ece Mutlu
Ruwaida Ben Musa, Graduate College, Rush University, Chicago, IL 60612, United States
Anuhya Gampa, Rush University, Chicago, IL 60612, United States
Sanjib Basu, Department of Preventive Medicine, Rush University, Chicago, IL 60612, United States
Ali Keshavarzian, Garth Swanson, Michael Brown, Rana Abraham, Keith Bruninga, John Losurdo, Mark DeMeo, Sohrab Mobarhan, David Shapiro, Ece Mutlu, Department of Gastroenterology and Nutrition, Rush University, Chicago, IL 60612, United States
Ece Mutlu, Department of Medicine, Clinical Research Section of Gastroenterology, Hepatology and Nutrition, Rush University, Chicago, IL 60612, United States
Author contributions: Ben Musa R collected, analyzed, interpreted the data, and wrote the paper; Gampa A wrote project protocol, set up data collection database and collected part of the data; Basu S reviewed all the statistics; Keshavarzian A, Swanson G, Brown M, Abraham R, Bruninga K, Losurdo J, DeMeo M, Mobarhan S and Shapiro D provided data and reviewed the manuscript; Mutlu E provided the hypotheses, designed the study, interpreted the data, supervised the data collection, analysis and wrote the paper; Mutlu E gave final approval of the version to be published.
Correspondence to: Ece Mutlu, MD, MS, MBA, Associate Professor, IBD Program Director, Department of Medicine, Clinical Research Section of Gastroenterology, Hepatology and Nutrition, Rush University, 1725 W. Harrison, Suite 206, Chicago, IL 60612, United States. ece_mutlu@rush.edu
Telephone: +11-312-563-3880 Fax: +11-312-563-3883
Received: November 23, 2013
Revised: May 31, 2014
Accepted: June 26, 2014
Published online: November 7, 2014
Processing time: 352 Days and 11.2 Hours
Core Tip

Core tip: With immunomodulatory drugs being used for treatment of inflammatory bowel disease (IBD) patients, it is important that IBD patients be protected against preventable infections, specifically hepatitis B. Compared to previous literature, the prevalence of hepatitis B virus (HBV) in IBD patients in a large tertiary gastroenterology practice in the United States was not higher than Europe. However, a significant portion of IBD patients were not routinely screened and vaccinated against HBV at a large tertiary gastroenterology practice. This corroborates the need for gastroenterologists and primary care physicians to be cognizant of treating IBD patients for preventable diseases in addition to managing IBD itself. Further education and use of electronic record prompters may be needed to increase prevention of HBV.